Turajlic lab

Cancer Dynamics Laboratory

: Areas of interest

This study focuses on understanding the immune response in clear cell renal cell carcinoma (ccRCC), which has a low to moderate tumour mutational burden (TMB) with a high incidence of frameshift mutations, potentially leading to increased neoantigen expression.

One of the fundamental questions in cancer evolution is the repeatability and stability of evolutionary trajectories.

Pathogenic germline mutations in the von Hippel-Lindau (VHL) gene cause a high penetrance autosomal dominant tumour predisposition syndrome, VHL Disease.

Tracking evolution of melanoma through therapy resistance. 

The VAULT study aims to tackle the challenge of intra-tumour heterogeneity in cancer, where multiple genetically distinct subclones exist within the same tumour, complicating accurate molecular profiling and treatment decisions.

Our research in the TRACERx Renal study aims to identify drivers and extent of intra-tumour heterogeneity in RCC and to determine how this heterogeneity impacts clinical outcomes.

While immune checkpoint inhibitors (ICIs) can produce durable responses in some cancer patients, their use is frequently associated with immune-related adverse events (irAEs).